Covaxin (BBV152) was well tolerated in children aged 2-18 years and induced higher neutralising antibody responses than those observed in adults in whom its efficacy (ie, the prevention or decrease in severity of Covid-19 infection) has been demonstrated. Bharat Biotech International Limited (BBIL), on Friday announced that BBV152 (Covaxin), its whole-virion inactivated Covid-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study.
